Insider · CIK 0001877793

Perry Andrew

Reports to the SEC for 1 company · RESEARCH TRIANGLE PARK, NC

sec.gov

Transactions

Companies

Filings

CIK

0001877793

Forms 4 and 5

Insider transactions

20 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-09-18	G1 Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+16.1K sh	—	—	128,714
2024-09-18	G1 Therapeutics, Inc.D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−114K sh	—	—	14,232
2024-09-18	G1 Therapeutics, Inc.U Disposition from Tender	Chief Commercial Officer	UDisposition from Tender	−14.2K sh	—	—	0
2024-09-18	G1 Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−67.1K sh	—	—	0
2024-09-18	G1 Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−32.1K sh	—	—	0
2024-07-05	G1 Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−1,337 sh	$2.51	−$3,352.795	112,614
2024-07-01	G1 Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+35K sh	—	—	113,951
2024-05-13	G1 Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−8,151 sh	$4.79	−$39K	78,951
2024-01-03	G1 Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+33.6K sh	—	—	89,515
2024-01-03	G1 Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−379 sh	$3.12	−$1,182.063	89,136
2024-01-03	G1 Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−2,034 sh	$3.12	−$6,343.843	87,102
2024-01-03	G1 Therapeutics, Inc.Stock Options (Right to Buy)A Award	Chief Commercial Officer	AAward	+67.1K sh	—	—	67,050
2023-07-05	G1 Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−355 sh	$2.45	−$871.064	55,945
2023-05-10	G1 Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+35K sh	—	—	56,300
2023-01-04	G1 Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−820 sh	$5.58	−$4,571.992	21,300
2023-01-03	G1 Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+16.1K sh	—	—	22,120
2023-01-03	G1 Therapeutics, Inc.Stock Options (Right to buy)A Award	Chief Commercial Officer	AAward	+32.1K sh	—	—	32,100
2022-01-03	G1 Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+6,000 sh	—	—	6,020
2022-01-03	G1 Therapeutics, Inc.Stock Options (Right to buy)A Award	Chief Commercial Officer	AAward	+26.5K sh	—	—	26,500
2021-08-16	G1 Therapeutics, Inc.Stock Options (Right to buy)A Award	Chief Commercial Officer	AAward	+300K sh	—	—	300,000

Recent filings

Accepted (ET)
Sep 184
Perry Andrew0000950170-24-107787
SEC(opens sec.gov)
Jul 84
Perry Andrew0001562180-24-005660
SEC(opens sec.gov)
Jul 34
Perry Andrew0001562180-24-005608
SEC(opens sec.gov)
May 154
Perry Andrew0001562180-24-004064
SEC(opens sec.gov)
Jan 84
Perry Andrew0001562180-24-000325
SEC(opens sec.gov)
Jul 74
Perry Andrew0001562180-23-005819
SEC(opens sec.gov)
May 124
Perry Andrew0001562180-23-004095
SEC(opens sec.gov)
Jan 54
Perry Andrew0001562180-23-000253
SEC(opens sec.gov)
Jan 54
Perry Andrew0001562180-22-000308
SEC(opens sec.gov)
Aug 174
Perry Andrew0001562180-21-005359
SEC(opens sec.gov)

Companies

G1 Therapeutics, Inc.Chief Commercial Officer

Address

700 PARK OFFICES DRIVE, SUITE 200

RESEARCH TRIANGLE PARK, NC, 27709